Federal regulators say they have approved the VenaSeal closure system to treat varicose veins
Covidien's VenaSeal closure system to treat varicose veins has been approved by the U.S. Food and Drug Administration, according to an agency press release.
Medtronic CEO Omar Ishrak tells analysts the company's managed services business for cath labs is expanding into new markets, with booked sales topping the $1 billion mark through its fiscal 3rd quarter.
Medtronic CFO Gary Ellis tells analysts that the $50 billion acquisition of Covidien pushes its available free cash flow from 35% to 60%, or about $7 billion annually.
Medtronic says its fiscal 3rd-quarter profits jumped nearly 30% as it tops Wall Street's forecast, without any contribution from Covidien.
Here's a look at some of the top legal news stories for medical device companies this week: Medtronic's new Ev3 unit pays $1.3m in whistleblower suit; Medtronic settles another whistleblower suit for $2.8m; Ex-NFL great Gault must face SEC fraud charges; Appeals court upholds Abiomed win in shareholders lawsuit; Pelvic mesh lawsuits: Boston Scientific wants 700 Philly cases sent to federal court
Studies of thrombectomy devices made by Medtronic's Covidien, Stryker and Penumbra show that they dramatically improve the likelihood that patients will recover from stroke.
(Reuters) - Grabbing and removing a clot blocking blood flow to the brain via thrombectomy, rather than just administering clot-busting drugs, dramatically improves the likelihood that patients will recover from a stroke, according to 2 highly-anticipated studies released today.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Medtronic's new Ev3 unit pays $1.3m in whistleblower suit; GPOs: Premier buys the rest of direct sourcer S2S Global; CareFusion crushes it in final quarter; BD beats Q1 estimates, raises outlook, shares jump; Zimmer revises Biomet bid for EU regulators